168 related articles for article (PubMed ID: 37894844)
21. Targeting the proteostasis network in Huntington's disease.
Soares TR; Reis SD; Pinho BR; Duchen MR; Oliveira JMA
Ageing Res Rev; 2019 Jan; 49():92-103. PubMed ID: 30502498
[TBL] [Abstract][Full Text] [Related]
22. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
[TBL] [Abstract][Full Text] [Related]
23. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
[TBL] [Abstract][Full Text] [Related]
24. Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
Kratter IH; Zahed H; Lau A; Tsvetkov AS; Daub AC; Weiberth KF; Gu X; Saudou F; Humbert S; Yang XW; Osmand A; Steffan JS; Masliah E; Finkbeiner S
J Clin Invest; 2016 Sep; 126(9):3585-97. PubMed ID: 27525439
[TBL] [Abstract][Full Text] [Related]
25. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Im W; Ban JJ; Chung JY; Lee ST; Chu K; Kim M
Sci Rep; 2015 Nov; 5():16887. PubMed ID: 26586297
[TBL] [Abstract][Full Text] [Related]
27. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
Lee CY; Cantle JP; Yang XW
FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
[TBL] [Abstract][Full Text] [Related]
28. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
[TBL] [Abstract][Full Text] [Related]
29. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
30. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
Chang R; Liu X; Li S; Li XJ
Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
[TBL] [Abstract][Full Text] [Related]
31. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
32. Bim contributes to the progression of Huntington's disease-associated phenotypes.
Roberts SL; Evans T; Yang Y; Fu Y; Button RW; Sipthorpe RJ; Cowan K; Valionyte E; Anichtchik O; Li H; Lu B; Luo S
Hum Mol Genet; 2020 Jan; 29(2):216-227. PubMed ID: 31813995
[TBL] [Abstract][Full Text] [Related]
33. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
34. Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex.
Li XJ; Zhang YY; Fu YH; Zhang H; Li HX; Li QF; Li HL; Tan RK; Jiang CX; Jiang W; Li ZX; Luo C; Lu BX; Dang YJ
Acta Pharmacol Sin; 2021 Oct; 42(10):1556-1566. PubMed ID: 33495516
[TBL] [Abstract][Full Text] [Related]
35. Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology.
Rieux M; Alpaugh M; Sciacca G; Saint-Pierre M; Masnata M; Denis HL; Lévesque SA; Herrmann F; Bazenet C; Garneau AP; Isenring P; Truant R; Oueslati A; Gould PV; Ast A; Wanker EE; Lacroix S; Cicchetti F
Mol Psychiatry; 2021 Sep; 26(9):5441-5463. PubMed ID: 32514103
[TBL] [Abstract][Full Text] [Related]
36. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
37. Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease.
Irvine EE; Katsouri L; Plattner F; Al-Qassab H; Al-Nackkash R; Bates GP; Withers DJ
Sci Rep; 2019 Nov; 9(1):16133. PubMed ID: 31695068
[TBL] [Abstract][Full Text] [Related]
38. Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.
Sanchis A; García-Gimeno MA; Cañada-Martínez AJ; Sequedo MD; Millán JM; Sanz P; Vázquez-Manrique RP
Exp Mol Med; 2019 Jun; 51(6):1-16. PubMed ID: 31165723
[TBL] [Abstract][Full Text] [Related]
39. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
40. The use of transgenic and knock-in mice to study Huntington's disease.
Hickey MA; Chesselet MF
Cytogenet Genome Res; 2003; 100(1-4):276-86. PubMed ID: 14526189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
